β-Blockers improve outcomes in kidney disease patients having noncardiac vascular surgery

Kidney International

Volumn 72, Issue 12, 2007, Pages 1527-1534

  Welten, G M J M ^a   Chonchol, M ^b   Hoeks, S E ^a   Schouten, O ^a   Bax, J J ^c   Dunkelgrun M ^a   Van Gestel, Y R B M ^a   Feringa, H H H ^a   Van Domburg, R T ^a   Poldermans, D ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Cardiovascular disease; Creatinine clearance; Kidney disease; Survival; Vascular surgery; blockers

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VASCULAR SURGERY;

EID: 36648999772     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002554     Document Type: Article

References (48)

1. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 1207-1216.
2. Xue JL, Ma JZ, Louis TA et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758.
3. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
4. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659-663.
5. Hua HT, Cambria RP, Chuang SK et al. Early outcomes of endovascular versus open abdominal aortic aneurysm repair in the National Surgical Quality Improvement Program-Private Sector (NSQIP-PS). J Vasc Surg 2005; 41: 382-389.
6. Wattanakit K, Folsom AR, Selvin E et al. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2007; 18: 629-636.
7. Yasuhara H, Ishiguro T, Muto T. Factors affecting late survival after elective abdominal aortic aneurysm repair. Br J Surg 1999; 86:1047-1052.
8. Back MR, Leo F, Cuthbertson D et al. Long-term survival after vascular surgery: specific influence of cardiac factors and implications for preoperative evaluation. J Vasc Surg 2004; 40: 752-760.
9. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381-386.
10. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
11. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variables predicting morbidity and mortality. J Vasc Surg 1989; 9: 437-447.
12. Hertzer NR, Mascha EJ, Karafa MT et al. Open infrarenal abdominal aortic aneurysm repair: the Cleveland Clinic experience from 1989-1998. J Vasc Surg 2002; 35: 1145-1154.
13. O'Hare AM. Management of peripheral arterial disease in chronic kidney disease. Cardiol Clin 2005; 23: 225-236.
14. Mangano DT, Layug EL, Wallace A et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335:1713-1720.
15. Poldermans D, Boersma E, Bax JJ et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-1794.
16. Lanfear DE, Jones PG, Marsh S et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005; 294: 1526-1533.
17. Hennekens CH, Braunwald E. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia, PA: WB Saunders, 1999.
18. Brophy JM, Joseph L, Rouleau JL. β-Blockers in congestive heart failure. Ann Inter Med 2002; 134: 550-560.
19. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001; 110(Suppl 7A): 81S-94S.
20. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
21. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
22. Blacher J, Safar ME, Guerin AP et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 1852-1860.
23. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
24. Muntner P, Hamm LL, Kusek JW et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17.
25. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
26. Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-46.
27. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 1905-1913.
28. Faber JE, Brody MJ. Neural contribution to renal hypertension following acute renal artery stenosis in conscious rats. Hypertension 1983; 5: 155-164.
29. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-727.
30. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576.
31. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-3244.
32. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15: 524-537.
33. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19: 1354-1357.
34. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int 2002; 62: 1784-1790.
35. Horl MP, Horl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17: 288-294.
36. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
37. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
38. Ishani A, Herzog CA, Collins AJ et al. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 2004; 65: 1017-1025.
39. Gibney EM, Casebeer AW, Schooley LM et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study. Kidney Int 2005; 68: 826-832.
40. McCullough PA. Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725-728.
41. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
42. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
43. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-1953.
44. Huynh TT, van Eps RG, Miller III CC et al. Glomerular filtration rate is superior to serum creatinine for prediction of mortality after thoracoabdominal aortic surgery. J Vasc Surg 2005; 42: 206-212.
45. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140-2144.
46. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
47. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35(Suppl 2): S1-S140.
48. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.